Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Lakeland Industries

Alpha Pro Tech

Why Novavax, Lakeland Industries, and Alpha Pro Tech Are Crashing Today

Gilead Sciences

Inovio Pharmaceuticals

Moderna

Vaxart

Here we discuss 5 biotech stocks that outperformed the industry amid the U.S. market slump.

5 Biotechs That Escaped the Coronavirus Onslaught Last Week

Co-Diagnostics

Progress with new COVID-19 tests and experimental vaccines in early-stage development sent these stocks flying higher.

3 Coronavirus Stocks That Soared Last Week

Clorox

These seven stocks could protect your portfolio against the SARS-CoV-2 outbreak.

7 Stocks to Buy as a Hedge Against The Coronavirus Threat

Vir Biotechnology

The viral outbreak is serious, but the latest numbers serve as a reminder for investors and individuals to remain objective about the health and economic risks.

Coronavirus: Emerging Numbers Provide Reasons for Calm

Regeneron Pharmaceuticals

Coronavirus work may give companies good press -- but resulting treatments won’t necessarily be a boon to earnings.

Here's Why Hype Around Companies Working on Coronavirus Treatments Is Overblown

Some of the top stocks in 2020 are the companies that are fighting the coronavirus.

3 Small-Caps That Are Soaring Because of Coronavirus Panic

GlaxoSmithKline

Johnson & Johnson

Sanofi

As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.

These 6 Drug Companies are Testing a Coronavirus Vaccine

These 6  Drug Companies are Testing a Coronavirus Vaccine

While most stocks and markets have taken big hits, these three coronavirus stocks have been among the most explosive opportunities.
The post 3 Coronavirus Stocks to Own Until the Fear Fades appeared first on InvestorPlace.

3 Coronavirus Stocks to Own Until the Fear Fades

Altimmune

NanoViricides

Zoom Video

The coronavirus fear is now a pandemic, at least in the markets. All major American averages were down over 3% on Friday, after what has been the worst week since the financial crisis more than a decade ago.

The Top Stocks to Beat the Coronavirus Market Scare

QIAGEN

While key players in the United States are struggling to cope, the coronavirus has been a boon for some.

3 Stocks Are Gaining Even as Coronavirus Creates Chaos

The COVID-19 inspired rally in these four biotech stocks is hitting fever pitch in pre-market action Thursday morning.

Why Inovio Pharmaceuticals, Gilead Sciences, Moderna, and Novavax Are All Jumping Today

The race is on to find a vaccine for the deadly Wuhan coronavirus -- and another drug company said Wednesday that it hopes it will be able to develop a successful drug.

Another coronavirus vaccine sends a biotech's stock soaring

Novavax Inc. (NASDAQ: NVAX) stock made a big step forward on Wednesday after the firm provided an update on its treatment for COVID-19.

How Novavax Is Differentiating Itself From Other Coronavirus Stocks

The clinical-stage biotech is evaluating multiple candidates it developed using its nanoparticle technology platform.

Novavax to Begin Clinical Testing of Coronavirus Vaccine by Late Spring

Investors are excited about the biotech's progress with its coronavirus vaccine program.

Why  Novavax Stock Is Soaring Today

GAITHERSBURG, Md., Feb.  26, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced progress in its efforts to develop a novel vaccine to protect against coronavirus disease COVID-19. Novavax has produced and is currently assessing multiple nanoparticle vaccine candidates in animal models prior to identifying an optimal candidate for human testing, which is expected to begin by the end of spring 2020.

Novavax Advances Development of Novel COVID-19 Vaccine

Healthcare companies are trying to find a cure and contain the coronavirus outbreak. This keeps the industry in focus

4 Healthcare Stocks to Gain as Coronavirus Threat Looms Large

Bicycle Therapeutics Plc - ADR

These two clinical-stage biotechs could yield exponential returns for early investors.

2 High-Growth Stocks I’m Buying Right Now

GAITHERSBURG, Md., Feb.  25, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced a publication in Vaccines describing the immunogenic potential of NanoFlu™, Novavax’ recombinant seasonal influenza vaccine candidate adjuvanted with Matrix-M™. The publication provides an in-depth comparison of vaccine antibody responses in mice compared to similar antibody responses in human subjects from historic clinical trials, highlighting the potential for NanoFlu to offer broadly protective immunity and improved vaccine efficacy. The publication is available online at  https://www.mdpi.com/2076-393X/8/1/99/htm .

Novavax’ Preclinical NanoFlu Data Published in Vaccines; Details Structural Basis for Broadly Neutralizing Immunity

Apple

iShares Russell 2000 ETF

Royal Caribbean Cruises

Starbucks

SPDR S&P Biotech ETF

My Initial Coronavirus Trading Plan

The COVID-19 respiratory disease is quickly morphing into a pandemic.

Why Inovio Pharmaceuticals and Novavax Are Exploding Higher Today

Virgin Galactic

How do we find the top stock of 2020? The best performers in 2019 offer some clues.

News for Novavax Stock (NVAX)